MetaVia Inc. (NASDAQ:MTVA) Shares Shorted: Short Interest Down 36.0% in September

MetaVia Inc. (NASDAQ:MTVA) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 117,409 shares, a decline of 36.0% from the September 15th total of 183,472 shares. Based on an average daily volume of 57,790 shares, the short-interest ratio is currently 2.0 days. Currently, 2.3% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

MTVA has been the subject of a number of research reports. Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a research note on Saturday, June 20th. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of MetaVia in a report on Friday, July 10th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MetaVia has an average rating of “Hold” and an average target price of $20.00.

MetaVia Stock Performance

Shares of NASDAQ MTVA traded down $0.11 during midday trading on Friday, hitting $1.26. 75,727 shares of the company’s stock traded hands, compared to its average volume of 64,310. MetaVia has a 1 year low of $0.97 and a 1 year high of $14.85. The stock has a market capitalization of $6.50 million, a price-to-earnings ratio of -0.39 and a beta of 0.96. The firm has a fifty day moving average of $1.57 and a 200 day moving average of $1.66.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). On average, equities analysts anticipate that MetaVia will post -2.79 earnings per share for the current year.

MetaVia Company Profile

MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s programs are designed to address conditions including excess weight, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease associated with metabolic dysfunction.

MetaVia’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed as a potential treatment for obesity and related metabolic complications.